These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36322383)

  • 1. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
    Futatsugi K; Cabral S; Kung DW; Huard K; Lee E; Boehm M; Bauman J; Clark RW; Coffey SB; Crowley C; Dechert-Schmitt AM; Dowling MS; Dullea R; Gosset JR; Kalgutkar AS; Kou K; Li Q; Lian Y; Loria PM; Londregan AT; Niosi M; Orozco C; Pettersen JC; Pfefferkorn JA; Polivkova J; Ross TT; Sharma R; Stock IA; Tesz G; Wisniewska H; Goodwin B; Price DA
    J Med Chem; 2022 Nov; 65(22):15000-15013. PubMed ID: 36322383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat.
    Sharma R; Dowling MS; Futatsugi K; Kalgutkar AS
    Chem Res Toxicol; 2023 Jun; 36(6):934-946. PubMed ID: 37148271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
    Sawant-Basak A; Bergman AJ; Mancuso J; Tripathy S; Gosset JR; Mendes da Costa L; Esler WP; Calle RA
    Clin Transl Sci; 2024 Feb; 17(2):e13687. PubMed ID: 38362827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
    Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C
    BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
    Amin NB; Carvajal-Gonzalez S; Purkal J; Zhu T; Crowley C; Perez S; Chidsey K; Kim AM; Goodwin B
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Postnatal Resolution of Developmental Toxicity Induced by Pharmacological Diacylglycerol Acyltransferase 2 (DGAT2) Inhibition During Gestation in Rats.
    Catlin NR; Bowman CJ; Campion SN; Lewis EM; Nowland WS; Stethem C; Cappon GD
    Toxicol Sci; 2022 Sep; 189(2):225-236. PubMed ID: 35866640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
    Calle RA; Amin NB; Carvajal-Gonzalez S; Ross TT; Bergman A; Aggarwal S; Crowley C; Rinaldi A; Mancuso J; Aggarwal N; Somayaji V; Inglot M; Tuthill TA; Kou K; Boucher M; Tesz G; Dullea R; Bence KK; Kim AM; Pfefferkorn JA; Esler WP
    Nat Med; 2021 Oct; 27(10):1836-1848. PubMed ID: 34635855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of Next-Generation DGAT2 Inhibitor PF-07202954 with Longer Predicted Half-Life.
    Filipski KJ; Edmonds DJ; Garnsey MR; Smaltz DJ; Coffman K; Futatsugi K; Lee J; O'Neil SV; Wright A; Nason D; Gosset JR; Orozco CC; Blackler D; Fakhoury G; Gutierrez JA; Perez S; Ross T; Stock I; Tesz G; Dullea R
    ACS Med Chem Lett; 2023 Oct; 14(10):1427-1433. PubMed ID: 37849537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
    Ganji SH; Kashyap ML; Kamanna VS
    Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core.
    Kim MO; Lee S; Choi K; Lee S; Kim H; Kang H; Choi M; Kwon EB; Kang MJ; Kim S; Lee HJ; Lee HS; Kwak YS; Cho S
    Biol Pharm Bull; 2014; 37(10):1655-60. PubMed ID: 25099343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
    Badi RM; Mostafa DG; Khaleel EF; Satti HH
    Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):545-555. PubMed ID: 30773673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ACC for NASH resolution.
    Zhang XJ; Cai J; Li H
    Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).
    Pabst B; Futatsugi K; Li Q; Ahn K
    Biochemistry; 2018 Dec; 57(51):6997-7010. PubMed ID: 30422629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of diacylglycerol O-acyltransferase (DGAT) isoforms in bovine hepatic fatty acid metabolism.
    Yang W; Wang S; Loor JJ; Lopes MG; Zhao Y; Ma X; Li M; Zhang B; Xu C
    J Dairy Sci; 2022 Apr; 105(4):3588-3600. PubMed ID: 35181144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.